It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic pathogen that infects patients with cystic fibrosis, burn wounds, immunodeficiency, chronic obstructive pulmonary disorder (COPD), cancer, and severe infection requiring ventilation, such as COVID-19. P. aeruginosa is also a widely-used model bacterium for all biological areas. In addition to continued, intense efforts in understanding bacterial pathogenesis of P. aeruginosa including virulence factors (LPS, quorum sensing, two-component systems, 6 type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation), rapid progress has been made in further studying host-pathogen interaction, particularly host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc. Furthermore, numerous technologic advances, such as bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy, have been used to improve our understanding of P. aeruginosa pathogenesis and host defense. Nevertheless, much remains to be uncovered about interactions between P. aeruginosa and host immune responses, including mechanisms of drug resistance by known or unannotated bacterial virulence factors as well as mammalian cell signaling pathways. The widespread use of antibiotics and the slow development of effective antimicrobials present daunting challenges and necessitate new theoretical and practical platforms to screen and develop mechanism-tested novel drugs to treat intractable infections, especially those caused by multi-drug resistance strains. Benefited from has advancing in research tools and technology, dissecting this pathogen’s feature has entered into molecular and mechanistic details as well as dynamic and holistic views. Herein, we comprehensively review the progress and discuss the current status of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection, which point out new directions for future investigation and add to the design of novel and/or alternative therapeutics to combat this clinically significant pathogen.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 West China Hospital, Sichuan University, Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
2 Wuhan University, State Key Laboratory of Virology, School of Public Health, Wuhan, P.R. China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153); University of North Dakota, Department of Biomedical Sciences, School of Medicine and Health Sciences, Grand Forks, USA (GRID:grid.266862.e) (ISNI:0000 0004 1936 8163)
3 University of North Dakota, Department of Biomedical Sciences, School of Medicine and Health Sciences, Grand Forks, USA (GRID:grid.266862.e) (ISNI:0000 0004 1936 8163)
4 City University of Hong Kong, Department of Biomedical Sciences, Hong Kong, People’s Republic of China (GRID:grid.35030.35) (ISNI:0000 0004 1792 6846)
5 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309)
6 Northwest University, College of Life Sciences, Xi’an, China (GRID:grid.412262.1) (ISNI:0000 0004 1761 5538)
7 West China Hospital, Sichuan University, Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022); University of North Dakota, Department of Biomedical Sciences, School of Medicine and Health Sciences, Grand Forks, USA (GRID:grid.266862.e) (ISNI:0000 0004 1936 8163)